Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Kidney Disease, Receiving Dialysis Clear all
Completed No phase listed Observational

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

NCT04487301
View directory record Official record
Conditions
Peripheral Artery Disease, End Stage Renal Disease on Dialysis
Interventions
Not listed
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 11:28 AM EDT
Recruiting Phase 3 Interventional

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions
AP301, AP301 Low Dose
Drug
Lead sponsor
Alebund Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Not applicable Interventional

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis , Full Scale Trial

NCT04194164
View directory record Official record
Conditions
Weight Gain
Interventions
Fluid intake app
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

NCT01290029
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2190 Days
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 23, 2026, 11:28 AM EDT
Completed No phase listed Observational Results available

HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis

NCT01343251
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

Pediatric Chronic Kidney Disease Safety and Efficacy

NCT01277510
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Jul 23, 2026, 11:28 AM EDT
Active, not recruiting Not applicable Interventional

Pain Reduction Using NEurostimulation Study

NCT05311956
View directory record Official record
Conditions
End Stage Kidney Disease, Chronic Pain
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated No phase listed Observational Results available

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

NCT01134315
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-Stage Renal Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Up to 16 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Gainesville, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Not listed Phase 4 Interventional

The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty

NCT03663049
View directory record Official record
Conditions
ESRD, Cardiovascular Diseases
Interventions
discontinue statin
Drug
Lead sponsor
Loyola University
Other
Eligibility
70 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

NCT02054572
View directory record Official record
Conditions
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Interventions
[¹⁴C]Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jul 23, 2026, 11:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2

NCT02212327
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

NCT01439867
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions
Cinacalcet hydrochloride, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2189 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

NCT02253654
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion
Interventions
Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Cerritos, California • Glendale, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
Interventions
AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
Drug
Lead sponsor
R1 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

NCT01750190
View directory record Official record
Conditions
CKD Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Jul 23, 2026, 11:28 AM EDT
Terminated Phase 1 Interventional Results available

Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

NCT00571194
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
pravastatin
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 23, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

NCT04622709
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Furosemide (loop diuretic) Tablets
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jul 23, 2026, 11:28 AM EDT